Heterocyclic compounds and their use in the treatment of mycobacterial infections
Heterocyclic compounds targeting Mycobacterium tuberculosis provide a promising solution to the challenge of multidrug-resistant tuberculosis by offering effective treatment options against mycobacterial infections.
Patent Information
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- GLAXOSMITHKLINE INTPROP DEV LTD
- Filing Date
- 2024-06-13
- Publication Date
- 2026-07-24
AI Technical Summary
The increasing emergence of multidrug-resistant strains of Mycobacterium tuberculosis and the persistently high incidence of tuberculosis pose a significant challenge in treatment, as current therapies require multiple drugs and struggle with resistance, necessitating the development of new compounds to effectively combat mycobacterial infections.
Development of heterocyclic compounds of formula (I) or their pharmaceutically acceptable salts, which can be administered alone or in combination with other antimycobacterial agents, to treat mycobacterial infections, including tuberculosis, by targeting Mycobacterium tuberculosis and other mycobacterial species.
These compounds demonstrate potential as effective treatments for tuberculosis and other mycobacterial infections, offering a therapeutic option against drug-resistant strains and reducing the reliance on multiple-drug regimens.
Smart Images
Figure 2026524817000001 
Figure 2026524817000002 
Figure 2026524817000003